Advertisement
Noticias de Forex
Euro Falls Against Majors
The euro slipped against its major counterparts in the European session on Monday.
RTTNews |
hace 639
U.S. New Home Sales Pull Back More Than Expected In October
The Commerce Department released a report on Monday showing new home sales in U.S. pulled back sharply in the month of October after soaring in September. The report said new home sales plunged by 5.6 percent to an annual rate of 679,000 in October after spiking by 8.6 percent to a downwardly revised rate of 719,000 in September.
RTTNews
|
hace 639
Lion Electric To Cut 150 Jobs Or 10% Of Total Headcount Amid Rationalization Of Cost Structure
Electric urban vehicles maker Lion Electric Co. (LEV, LEV.TO) announced Monday a workforce reduction aimed at rationalizing its cost structure and improving its ability to reach its profitability objectives.
RTTNews
|
hace 639
89bio Reports Positive Topline Data From Extended Phase 2b ENLIVEN Trial Of Pegozafermin
Biopharmaceutical company 89bio, Inc. (ETNB) announced Monday positive topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).
RTTNews
|
hace 639
GRI Bio Says FDA Clears IND For GRI-0621 For Treatment Of IPF; Stock Up 19%
Biotechnology company GRI Bio, Inc. (GRI) announced Monday that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for GRI-0621 for the treatment of IPF.
RTTNews
|
hace 639
Another Week Of Dollar Weakness Despite Hawkish Fed Minutes
Renewed rate cut hopes dragged the U.S. Dollar lower during the week ended November 24, notwithstanding a hawkish tone in the Fed minutes released on Tuesday.
RTTNews
|
hace 639
Collegium Says Appeals Court Upholds PTAB's Finding Of Invalidity Of Purdue's 961 Patent Claim
Collegium Pharmaceutical, Inc. (COLL) announced Monday that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue's '961 patent, which Purdue Pharma L.P. has claimed is infringed by Xtampza ER, is invalid.
RTTNews
|
hace 639
more news
Outlook Therapeutics Announces Receipt Of Type A Meeting Official Minutes On ONS-5010 BLA
Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday the receipt of the official minutes from the Type A meeting with the U.S. Food and Drug Administration (FDA) held in October 2023.
RTTNews
|
hace 639
Bay Street Likely To Open On Cautious Note
Canadian shares are likely to open on a cautious note on Monday with investors awaiting a slew of key economic data from Canada and the U.S. Concerns about economic slowdown in China and weak crude oil prices are likely to weigh on the market.
RTTNews
|
hace 639
U.S. Dollar Dips Ahead Of Key Data
The U.S. dollar weakened against its major counterparts in the European session on Monday on bets that the Federal Reserve is done hiking interest rates.
RTTNews
|
hace 639
Summit Materials Plans To Offer $800.0 Million Aggregate Principal Amount Of Senior Notes Due 2031
Summit Materials, Inc. (SUM) announced Monday that its indirect subsidiaries Summit Materials, LLC and Summit Materials Finance Corp. intend to offer $800.0 million aggregate principal amount of Senior Notes due 2031.
RTTNews
|
hace 639
Krystal Biotech Says EMA Validated MAA For VYJUVEK For Dystrophic Epidermolysis Bullosa
Biotechnology company Krystal Biotech, Inc. (KRYS) announced Monday that the Company's Marketing Authorization Application (MAA) to the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for VYJUVEK (beremagene geperpavec-svdt or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) has been validated and is now under CHMP review. A CHMP opinion is anticipated in the second half of 2024.
RTTNews
|
hace 639
Genelux Says FDA Grants Fast Track Designation For Olvi-Vec To Treat Ovarian Cancer
Immuno-oncology company Genelux Corp. (GNLX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.
RTTNews
|
hace 639
Stay up to date!
Add Noticias to your browser
Add To Chrome
